drugset / Trial / NCT05528341
NKG2D-CAR-NK92 Cells Immunotherapy for Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this clinical investigation is to evaluate the safety and effects of NKG2D-CAR-NK92 infusions in the treatment of relapsed/refractory solid tumors.
Timeline
- Start
- 2023-01-26
- Primary completion
- 2026-04
- Completion
- 2026-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NKG2D-CAR-NK92 cells | Cell therapy | 500000 cells/kg | Intravenous |
| Subject | NKG2D-CAR-NK92 cells | Cell therapy | 2e+06 cells/kg | Intravenous |